In a previous study from our group, we reported that the Mel-18 gene functioned as a tumor suppressor in prostate cancer, and a SNP (1805A/G) in the miRNA-181a binding site correlated with Mel-18 expression and clinical features in prostate cancer [18]. This evidence concerns the gene PCGF2 and prostate carcinoma.